17.00
price up icon3.34%   0.55
after-market Handel nachbörslich: 17.00
loading
Schlusskurs vom Vortag:
$16.45
Offen:
$16.63
24-Stunden-Volumen:
2.84M
Relative Volume:
2.88
Marktkapitalisierung:
$2.13B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-12.14
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-11.04%
1M Leistung:
+4.10%
6M Leistung:
-39.20%
1J Leistung:
-23.25%
1-Tages-Spanne:
Value
$16.55
$17.32
1-Wochen-Bereich:
Value
$16.22
$19.11
52-Wochen-Spanne:
Value
$14.17
$34.13

Novocure Ltd Stock (NVCR) Company Profile

Name
Firmenname
Novocure Ltd
Name
Telefon
44 (0)15 3475 6700
Name
Adresse
NO. 4 THE FORUM, ST. HELIER
Name
Mitarbeiter
1,488
Name
Twitter
@novocure
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
NVCR's Discussions on Twitter

Vergleichen Sie NVCR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
NVCR
Novocure Ltd
17.00 2.13B 577.74M -149.78M -78.21M -1.40
Medical Devices icon
ABT
Abbott Laboratories
133.58 232.41B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
102.09 155.73B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
383.89 146.23B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
87.44 106.37B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
77.52 45.88B 5.54B 4.18B 623.10M 7.00

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-02 Hochstufung Evercore ISI In-line → Outperform
2024-10-16 Hochstufung H.C. Wainwright Neutral → Buy
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-08-28 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-08 Hochstufung Piper Sandler Neutral → Overweight
2023-08-04 Eingeleitet SVB Securities Outperform
2023-07-31 Hochstufung Evercore ISI Underperform → In-line
2023-06-07 Hochstufung Wedbush Underperform → Neutral
2023-05-16 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-17 Herabstufung JP Morgan Neutral → Underweight
2023-01-06 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-05 Bestätigt H.C. Wainwright Buy
2022-11-29 Hochstufung Wells Fargo Equal Weight → Overweight
2022-10-24 Herabstufung Piper Sandler Overweight → Neutral
2022-07-05 Herabstufung Evercore ISI In-line → Underperform
2022-05-16 Eingeleitet H.C. Wainwright Buy
2022-02-08 Eingeleitet Loop Capital Buy
2022-02-02 Hochstufung Oppenheimer Perform → Outperform
2022-01-20 Hochstufung Truist Hold → Buy
2022-01-03 Hochstufung Evercore ISI Underperform → In-line
2021-07-01 Herabstufung Mizuho Buy → Neutral
2021-04-14 Herabstufung Wedbush Neutral → Underperform
2021-01-25 Bestätigt Piper Sandler Overweight
2020-09-23 Eingeleitet Northland Capital Outperform
2020-09-18 Herabstufung Wells Fargo Overweight → Equal Weight
2020-09-17 Herabstufung Truist Buy → Hold
2020-06-01 Fortgesetzt Oppenheimer Perform
2020-05-01 Herabstufung Oppenheimer Outperform → Perform
2020-04-09 Herabstufung Evercore ISI In-line → Underperform
2020-03-05 Hochstufung Wells Fargo Equal Weight → Overweight
2020-01-02 Herabstufung Evercore ISI Outperform → In-line
2019-07-29 Hochstufung SunTrust Hold → Buy
2019-07-26 Herabstufung JP Morgan Overweight → Neutral
2019-07-26 Herabstufung Wedbush Outperform → Neutral
2019-03-20 Eingeleitet SunTrust Hold
2018-11-02 Herabstufung Wells Fargo Outperform → Market Perform
2018-07-16 Eingeleitet Evercore ISI Outperform
2018-04-18 Bestätigt Mizuho Buy
2018-02-23 Bestätigt Mizuho Buy
2017-05-24 Hochstufung Wells Fargo Market Perform → Outperform
2016-07-29 Bestätigt Wedbush Outperform
2016-01-19 Eingeleitet Barclays Underweight
2015-12-02 Eingeleitet Deutsche Bank Hold
Alle ansehen

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

pulisher
Jun 06, 2025

NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks

Jun 01, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus

May 31, 2025
pulisher
May 31, 2025

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance

May 31, 2025
pulisher
May 30, 2025

NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus

May 30, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Lowers Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

May 28, 2025
pulisher
May 27, 2025

Novocure Announces Upcoming Investor Events | NVCR Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Novocure Announces Upcoming Investor Events - Yahoo Finance

May 27, 2025
pulisher
May 22, 2025

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

May 22, 2025
pulisher
May 22, 2025

BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 22, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Sells 3,016 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 17, 2025
pulisher
May 15, 2025

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - Yahoo Finance

May 15, 2025
pulisher
May 12, 2025

Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

May 12, 2025
pulisher
May 11, 2025

Raymond James Financial Inc. Purchases Shares of 11,672 NovoCure Limited (NASDAQ:NVCR) - Defense World

May 11, 2025
pulisher
May 10, 2025

Investor Network: Novocure Ltd. to Host Earnings Call - ACCESS Newswire

May 10, 2025
pulisher
May 10, 2025

NovoCure Limited (NASDAQ:NVCR) Given Average Rating of “Moderate Buy” by Analysts - Defense World

May 10, 2025
pulisher
May 09, 2025

NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 20.62, Down -3.28 - DWinneX

May 09, 2025
pulisher
May 07, 2025

Envestnet Asset Management Inc. Buys New Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

May 07, 2025
pulisher
May 07, 2025

Mariner LLC Acquires Shares of 8,631 NovoCure Limited (NASDAQ:NVCR) - Defense World

May 07, 2025
pulisher
May 06, 2025

Comparing Meihua International Medical Technologies (NASDAQ:MHUA) & NovoCure (NASDAQ:NVCR) - Defense World

May 06, 2025
pulisher
May 02, 2025

Ratio Analysis: Unpacking NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 02, 2025
pulisher
May 02, 2025

A year in review: NovoCure Ltd (NVCR)’s performance in the last year - uspostnews.com

May 02, 2025
pulisher
Apr 29, 2025

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

NovoCure Ltd’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

What is NovoCure Ltd (NVCR) Stock Return on Shareholders’ Capital? - Sete News

Apr 28, 2025
pulisher
Apr 28, 2025

Russell Investments Group Ltd. Sells 2,135 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 28, 2025
pulisher
Apr 26, 2025

NovoCure First Quarter 2025 Earnings: Beats Expectations - simplywall.st

Apr 26, 2025
pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on NovoCure, $38 price target By Investing.com - Investing.com Canada

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure Ltd [NVCR] Shares Jump Approximately 56.80% Over the Year - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Why NovoCure Stock Skyrocketed This Week - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

H.C. Wainwright maintains Buy on NovoCure, $38 price target - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure (NASDAQ:NVCR) Cut to “Sell” at StockNews.com - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure (NASDAQ:NVCR) Shares Gap Up After Earnings Beat - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

NovoCure: Q1 Earnings Snapshot - Huron Daily Tribune

Apr 25, 2025
pulisher
Apr 25, 2025

Bank of Montreal Can Buys New Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Novocure’s Q1 2025: Revenue Growth and Strategic Advances - TipRanks

Apr 25, 2025

Finanzdaten der Novocure Ltd-Aktie (NVCR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novocure Ltd-Aktie (NVCR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
LEUNG GABRIEL
Director
Jun 03 '25
Sale
17.31
999
17,297
81,229
Madden Martin J.
Director
Jun 03 '25
Sale
17.19
999
17,176
18,674
Scannell Timothy J
Director
Jun 03 '25
Sale
17.32
999
17,299
6,018
HILLEMAN JERYL L
Director
Jun 03 '25
Sale
17.26
999
17,247
5,591
Ocean Allyson J
Director
Jun 03 '25
Sale
17.29
999
17,269
3,054
VERNON W ANTHONY
Director
Jun 03 '25
Sale
17.35
999
17,329
167,887
Hung David
Director
Jun 03 '25
Sale
17.30
999
17,280
12,195
Leonard Frank X
EVP, Pres., Novocure Oncology
Jun 02 '25
Sale
17.50
30,196
528,413
168,452
medical_devices PHG
$23.46
price up icon 0.56%
$311.77
price down icon 1.70%
medical_devices STE
$243.72
price up icon 0.06%
$71.62
price up icon 0.10%
$86.67
price up icon 1.08%
medical_devices EW
$77.52
price down icon 0.32%
Kapitalisierung:     |  Volumen (24h):